SUMMARY To evaluate the rat as an experimental model for plasminogen activator research, the ability of antibodies specific for human tissue type plasminogen activator and urokinase to suppress the plasminogen activator activity in whole plasma and in the vessel wall was studied in both rat and man. Plasminogen activator activity in plasma was assayed on fibrin plates containing plasminogen. Plasminogen activator in the vessel wall was shown by the fibrin slide techniqde. Antibodies against human tissue type melanoma cell activator and urokinase were raised in goats and mixed into the fibrin film or the fibrin plates. In both species antibodies'-to melanoma cell activator were able to suppress the plasminogen activator activity completely in plasma and in the vessel wall. Anti-urokinase, however, had no suppressing effect. In rat plasma the inhibitory effect on the fibrinolytic activity was seen only with high concentrations of antibodies against melanoma cell activator, which suggests that rat plasminogen activator in plasma and vessel walls is similar-to, but not identical with, human tissue type plasminogen activator.
Plasminogen activators a-specific proteolytic enzymes.-which'--convert the inactive plasminogen .into.:tive plasmin, thereby initiating the fibrinolytic system.' Int--lissues and body fluids two types of plasminogen activator have been identified: tissue like and urokinase like plasminogen activators. In blood the tissue like plasminogen activator is the main type present, and there are only small amounts of urokinase like plasminogen activators. 23 The fibrinolytic system can also be activated by an additional mechanism that is dependent on factor XII, high molecular weight kininogen, and prekallekrein. 4 Most malignant tumours produce urokinase like plasminogen activators.56 A melanoma cell line has been found to produce a tissue like plasminogen activator, which is similar to and cross reacts with the tissue like plasminogen activators from the human uterus.7 8 Cultures of this melanoma cell line have made it possible to obtain plasminogen activator in sufficient amounts for immunisation and further research. In human plasma, the plasminogen activator activity was suppressed by antibodies directed against tissue like plasminogen activators Accepted for publication 11 July 1984 from human uterus, porcine heart, or human melanoma cells.9-i In tissues, such as the ureter and the vein wall, the plasminogen activatoK activity was suppressed by antibodies specific for tissue like plasminogen activators, whereas antibodies to urokinase had no inhibitory effect. '2 diluted 1/100, 1/1000, and 1/6000, while the final dilution in the fibrin slides was 1/100. Fibrinolytic activity in whole plasma on the fibrin plates containing IgG were determined in duplicate, with the controls determined in triplicate.
Results
The spontaneous fibrinolytic activity in plasma applied to fibrin plates with and without antibodies is shown in the Table. In human plasma antibodies to melanoma cell activator completely suppressed the fibrinolytic activity after venous occlusion for 3 min. After 10 min occlusion, the fibrinolytic activity was hardly measurable on addition of melanoma cell activator at the 1/6000 dilution. In all rat plasma samples the fibrinolytic activity was completely suppressed by antibodies to melanoma cell activator in the 1/100 dilution. No inhibitory effect of antibodies to melanoma cell activator was seen at greater dilutions. In both species the fibrinolytic activity in plasma samples applied to fibrin plates containing normal IgG or anti-urokinase varied within the range of the control plates as shown in the Table. In the control fibrin slides the lysed areas over the vessel sections increased with incubation time. No inhibitory effect on the plasminogen activator activity in the vessel wall was seen after the addition of anti-urokinase or control IgG to the fibrin film. On the contrary, even at the shortest incubation period the fibrinolytic activity of human and rat vessel walls was completely suppressed in the fibrin films containing antibodies to melanoma cell activator. The absence of lysis in the fibrin films with antibodies to Immunological comparison between human and rat plasminogen activators melanoma cell activator is illustrated in the Figure, which shows the fibrinolytic activity of the vessel specimens after 120 min incubation with and without antibodies added to the fibrin film.
Discussion
A recent report on the immunological characterisation of the plasminogen activator in the human vein wall showed that the fibrinolytic activity was initiated by tissue like plasminogen activators. '2 This observation was confirmed in the present study, in which antibodies to melanoma cell activator completely suppressed the plasminogen activator activity in the vessel wall of man and also of the rat. Anti-urokinase had no inhibitory effect even after a prolonged incubation period of 2 h. In both species, the plasminogen activator activity in citrated whole plasma could be completely suppressed by antibodies to melanoma cell activator. No significant inhibitory effect of anti-urokinase was shown, although small amounts of urokinase in human plasma have been reported.23 A slight inhibitory effect of anti-urokinase could be explained by similarities of the urokinase and melanoma cell activator molecules. 24 Immunological similarity was thus shown between the vascular and blood plasminogen activator in man and rat. This observation implies that the relatively high fibrinolytic activity seen in active rats is probably caused by tissue like plasminogen activators being released from vessels by the same mechanism as in man. Dilution of the IgG fraction containing antibodies to melanoma cell activator resulted in the loss of its inhibitory capacity on the rat plasma, while considerably lower concentrations still suppressed the plasminogen activator activity in the human plasma samples which had higher initial fibrinolytic activity. Moreover, in a previous comparative study on plasminogen activator from human uterus and from a rat brain tumour cell line, the rat plasminogen activator was less susceptible to the inhibitory effect of antibodies specific for human uterine plasminogen activator, although these antibodies at high concent-1156 rations completely suppressed the rat plasminogen activator activity.25 Hence, antibodies to melanoma cell activator seem to bind more firmly to human than to (at plasminogen activator.
In conciusion, the rat tissue like plasminogen activators are similar to, but probably not identical with, the human tissue like plasminogen activators. In rats, as in man, the tissue like plasminogen activators are present jn plasma as well as in the vessel wall. The firmer binding of antibodies against melanoma cell activator to human plasminogen activator indicates minor species related differences in the structure of the otherwise closely related plasminogen activators of these-two species. In man vascular plasminogev activators are important regulators of the fibrinolytic activity' in blood. Absence of immunological. differences between the rat plasma plasminogen activator and the vessel wall plasminogen activator indicates a similar central position of tissue like plasminogen activators in the fibrinolytic system of the rat. This work '' was supported by grants from Swedish Medical Research Council (B84-17X-04523-1OA) and Swedish Tobacco Company (8227). We thank Dr Christopher Korch for carefully reading the manuscript.
